Table 1 Percentage of institutions receiving alerts, by measure

Mean alerts per month per CCG/practice

(2.5)

(2.4)

(1.3)

(1.4)

Mean %, all measures

7.7

7.5

3.9

4.3

Topical treatment of fungal nail infections

5.3

6.2

2.1

2.9

High-cost PPIs

7.2

7.2

3.1

3.9

High cost tramadol preparations

2.4

3.3

4.6

4.4

High-cost drugs for erectile dysfunction

6.2

6.7

3.7

4.4

High-cost ARBs

6.7

4.3

2.7

2.7

High dose inhaled corticosteroids

14.4

12.9

5.8

5.1

Prescribing of dipyridamole

7.7

7.7

5.0

5.0

Methotrexate 10 mg tablets

5.3

7.7

2.7

3.1

Vitamin B complex

16.3

8.6

5.0

5.0

Soluble/effervescent forms of paracetamol and co-codamol

6.7

3.3

4.0

4.2

Non-preferred NSAIDs and COX-2 inhibitors

2.9

4.3

3.4

4.4

Other lipid-modifying drugs

8.1

6.7

4.7

3.9

Direct Oral Anticoagulants (DOACs)

14.4

15.3

4.5

4.9

Silver dressings

5.3

5.7

2.8

3.2

Long-acting insulin analogues

6.7

7.7

3.2

3.9

Volume of antibiotic prescribing

5.3

4.8

4.9

5.0

Prescribing of pregabalin

12.0

12.9

5.6

5.4

Diltiazem preparations prescribed generically

12.0

12.4

4.0

6.6

Co-proxamol

8.1

5.3

1.0

4.6

High dose opioids

4.8

6.2

5.8

5.5

Ciclosporin and tacrolimus oral preparations prescribed generically

2.9

5.7

1.4

2.2

Desogestrel prescribed as a branded product

11.5

12.4

4.6

6.2

Nebivolol 2.5mg tablets

7.2

6.7

3.1

2.6

Three-day antibiotic courses for UTIs

3.8

2.9

2.9

3.5

High-cost ACE inhibitors

2.4

2.4

1.7

3.0

High-cost statins

4.8

8.6

3.4

3.9

Glaucoma eye drops prescribed by brand

12.0

9.1

4.0

4.8

Higher dose Proton Pump Inhibitors

14.8

12.9

7.1

8.3

Co-amoxiclav, cephalosporins & quinolones

11.0

8.6

4.6

4.8

Extended-release quetiapine

11.5

7.7

6.2

5.9

Short acting beta agonist inhalers

3.8

8.6

3.5

3.0

Keppra vs. levetiracetam

5.3

4.3

3.3

2.7